TB-500, explained.
Thymosin beta-4 fragment. Research, safety questions, and treatment context.
The form
Preparation matters
The routine
No personal schedule is set by this guide.
The evidence
See the evidence and source notes below.
Research, approval and availability are separate questions.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- Backed by FDA advisers, awaiting final rule
FDA advisers voted 8 to 6 on July 23, 2026 to allow compounding for wound healing. Not compoundable until the final rule.
- At Goodmorrow
- Waitlist open
What it is
TB-500 is a lab-made fragment of thymosin beta-4, a protein your cells use to move into and rebuild injured tissue. It was used in racehorses long before it reached people.
People take it for muscle, tendon and joint recovery, usually alongside BPC-157. That pairing is called the Wolverine stack.
What the evidence shows
The case for TB-500 rests on animal and lab studies of the full thymosin beta-4 protein in wound healing and heart tissue. There's very little human data on the fragment itself. The FDA's July review looked at wound healing.
How Goodmorrow handles it
We'll prescribe it through a licensed pharmacy once the FDA finalizes the rule, not before. When we do, it will be dosed on its own, not pre-mixed, so your clinician can adjust it independently.
Before you take it
- Prohibited in tested sport under the World Anti-Doping Code.
Stacks that include it
- Wolverine stack: bpc-157 and tb-500 for injury recovery
- GLOW stack: ghk-cu, bpc-157 and tb-500 for skin and repair
- KLOW stack: glow plus kpv
Follow updates about TB-500
Join the update list. This does not reserve a treatment or mean that future availability is assured.
Questions people ask
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the full natural protein. TB-500 is a short synthetic fragment of it. Most of the research is on the full protein, so the results don't transfer cleanly.
When will TB-500 be available in Dallas?
When the FDA finalizes the July 2026 recommendation and licensed pharmacies can compound it. There's no firm date. The list is the fastest way to hear when it changes.
Sources
- FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
- Secondary sourceFDA Panel Votes to Loosen Restrictions for Four Peptides PharmExec, July 2026
- Secondary sourceFDA advisory committee nominates six peptides for pharmacies to compound National Community Pharmacists Association, July 31, 2026
- Secondary sourceTB-500: Status, Risks, and Bans in Sport and Military BSCG
Good days ahead.
Join the opening list for appointment updates.